Takeda Open to More Deals

After spending nearly $15 billion on overseas acquisitions in less than two years, Japan’s top drugmaker, Takeda Pharmaceutical, is not ruling out further deals as it looks to overcome patent expiries and cement its position as a global industry player.
The Wall Street Journal